Back to News
Market Impact: 0.3
Telix Targets $1.5 Bln Revenue In 2027 As ITM Deal May Accelerate Therapy Launch To 2027
Source: Nasdaq
Corporate Guidance & OutlookM&A & RestructuringHealthcare & BiotechCompany Fundamentals
Telix Pharmaceuticals is targeting approximately $1.5 billion in revenue in 2027, including an anticipated contribution from its proposed acquisition of ITM Isotope Technologies Munich SE. The article excerpt provides no further deal terms or details on the revenue outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
TLX0.35
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Shield AI To Hit $28.8 Billion Value With $5.3 Billion Radar Acquisition
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request